2022 GBT2104-133 – An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

Previous Post2021 GBT2104-131 – A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises
Next Post2021 AG348-C-020 ‘Agios’ – Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease